US pharmaceutical major Eli Lilly & Co. (NYSE: LLY) has announced the expansion of its manufacturing facility in Kenosha County, Wisconsin, with a substantial capital investment of USD 3 billion. This significant expansion, acquired earlier this year, is part of Lilly’s strategic plan to enhance its global parenteral (injectable) product manufacturing network.
Boosting Production Capacity to Meet Growing Demand
The investment is aimed at increasing production capacity to meet the rising demand for Lilly’s diabetes and obesity treatments, as well as to accommodate future pipeline medicines across various therapeutic areas. This move underscores Lilly’s commitment to strengthening its manufacturing capabilities to serve patients more effectively.
Construction and Job Creation
Construction for the expansion is scheduled to commence next year. Upon completion, the facility is expected to add 750 highly skilled jobs to the existing workforce of over 100 employees, significantly contributing to the local economy and employment landscape.-Fineline Info & Tech
